Document Status

This document has been corrected

Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)

10.1186/s12885-018-4663-4

Published Online: 2018-07-24

Journal: BMC Cancer•Publisher: Springer Science and Business Media LLC

Authors: Antonio Sa Cunha•Dewi Vernerey•Fabienne Portales•Jean-Baptiste Bachet•Jean-Jacques Tuech•Lilian Schwarz•Pierre Michel

This document has been corrected

Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)

10.1186/s12885-018-4663-4

Published Online: 2018-07-24

Journal: BMC Cancer

Authors: Antonio Sa Cunha•Dewi Vernerey•Fabienne Portales•Jean-Baptiste Bachet•Jean-Jacques Tuech•Lilian Schwarz•Pierre Michel

NOW

2020-03-03•Correction

Correction to: Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)

10.1186/s12885-020-6678-x

* information provided by CrossRef

2020-03-03•Correction

10.1186/s12885-020-6678-x

* information provided by CrossRef

2018-07-24•Published